期刊文献+

静脉药物配置中心24h运行模式下批量配置顺铂方法探讨 被引量:3

原文传递
导出
摘要 目的探讨静脉用药调配中心(PIVAS)批量配置顺铂的操作方法,以保证患者及时、准确用药。方法实验组和对照各200支顺铂。实验组将顺铂充人溶媒后放振荡器振荡1min后放人恒温水浴中,根据水温将实验组分为5个亚组,每亚组40支顺铂,即A组(水温46oC)、B组(水温48oC)、C组(水温50oC)、D组(水温52℃)、E组(水温54℃)。 Objective To explore the suitable way of batch cisplatin dissolution in pharmacy intravenous admixture service (PIVAS) and ensure the patients' receive medicine timely and accurately.Methods All samples were divided into control group and experiment group,with 200 cisplatinum in each group.The control group added dissolvent and then oscillated for 30 min,and the dissolve time of cisplatin was observed.The experiment group put the cisplantin into warm water after oscillation for 1 min.According to the water temperature,five subgroups were divided into five subgroups with each group 40 cisplantin:subgroup A (water temperature 46 ℃ ),subgroup B ( water temperature 48 ℃ ),subgroup C ( water temperature 50 ℃ ),subgroup D( water temperature 52 ℃ ) and subgroup E( water temperature 54 ℃ ).The state of cisplatin dissolve every one minute and dispensing time were recorded.Results Compared with the control group,the cisplatin in the experiment group was solved more completely,and the difference was statistically significant( x2 =9.087,P<0.05).With the step-up of water temperature,the number of the dissolved cisplatin in 5 min of experimental subgroups gradually increased,subgroup A,9 cases (22.5%) ;subgroup B,28 cases (70%) ;subgroup C,34 cases (85%) ;subgroup D,40 cases ( 100% ),and 33 cases in subgroup D,40 cases in subgroup E within 3 min.Conclusions In PIVAS 24-h continuous mode,the way of cisplatin dissolve by heat and oscillation for 1 min,with the water temperature keeps 52 ℃ and dissolve time in 5 min is a faster and effective method.This mode can save time and improve efficiency.
出处 《中华现代护理杂志》 2012年第17期2088-2091,共4页 Chinese Journal of Modern Nursing
  • 相关文献

参考文献10

  • 1Jordana P, Carmo-Fonseca M. Molecular mechanisms involved in cisplatin cytotoxicity. Cell Mol Life Sci, 2000,57 ( 8-9 ) : 1229- 1235.
  • 2Markman M. New, expanded, and modified use of approved antineoplastic agents in ovarian cancer. Oncologist,2007,12 (2) : 186-190.
  • 3Zorat PL, Paccagnella A, Cavaniglia G, et al. Randomized phase III trial of neoadjuvant chemotherapy in head and neck cancer: 10-year follow-up. J Natl Cancer Inst, 2004,96 ( 22 ) : 1714- 1717.
  • 4Strumberg D, Brtigge S, Korn MW,et al. Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non- seminomatous testicular cancer. Ann Oncol, 2002,13(2):229-236.
  • 5Gholam D, Fizazi K, Terrier-Lacombe MJ, et al. Advanced seminoma-treatment results and prognostic factors for survival after first-line, cisplatin-based chemotherapy and for patients with recurrent disease: a single-institution experience in 145 patients. Cancer, 2003,98(4) :745-752.
  • 6Wakelee H, Belani CP. Optimizing first-line treatment options for patients with advanced NSCLC. Oncologist,2005 ,Suppl(3) :1-10.
  • 7Abratt RP, Hart GJ. 10-year update on chemotherapy for non- small cell lung cancer. Ann Oneol, 2006, Suppl(5 ) :v33-v36.
  • 8罗云,何文,李荣凌.顺铂注射剂的稳定性研究[J].江西中医学院学报,2005,17(2):58-59. 被引量:1
  • 9邵孝珙,迟宝兰.临床药物学//基层全科医生诊疗指南.北京:学苑出版社,2006:128-129.
  • 10李斌,高克力,苏聪,王永昌,那光玮.顺铂稳定性实验观察[J].甘肃医药,2010,29(5):578-580. 被引量:8

二级参考文献6

共引文献7

同被引文献42

引证文献3

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部